Abstract: The present invention relates to a method for synthesizing diversely substituted purines starting from a pyrimidine. Formula (I). The method comprises the formation of an amidine group on the pyrimidine by implementing a Vilsmeier type reagent, the functionalization of the pyrimidine with an amine and the cyclization to form the purine nucleus. Optional steps can also be performed in order to further functionalize the molecule. The invention also relates to new purines and new intermediate product.

Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

Abstract: The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make them useful for inhibiting translation of target mRNA in vivo.

Abstract: This invention concerns compounds with the formula: in which: R1?OH or NH2; OR2, OR3, OR4 and OR5 are alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate groups; and if R5?H if R2?R3?R4, then R2, R3 and R4?H; if R2?H, then R3?H and R4?H; if R3?H, then R2?H and R4?H; if R4?H, then R2?H and R3?H; if R5?H if R2=H, then R3?H and R4?H; if R3?H, then R2?H and R4?H; if R4?H, then R2?H and R3?H, their use as antibiotic agents and the process for synthesizing them.

Abstract: Process for preparing a compound of the formula (I) R1-S(O)x—S(O)yR2 in which R1 represents a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen; R2, independently of R1, represents a carbon-containing group or a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen, and x and y are selected from 0 and 1 in such a way that the sum of x and y is not more than 1, characterized in that a compound of formula (II) R1-S(O)x—R3-Si(R4)(R5)(R6) in which R3 represents a hydrocarbon chain of two carbon atoms, which is optionally unsaturated and/or substituted, and R4, R5 and R6, which are identical or different, each represent, independently of one another, a

Abstract: The invention relates to the use of compounds as new chiral selectors for separating the optical or enantiomeric isomers of a compound, wherein the chiral selector comprises at least one compound of formula (I): and at least one metal ion, for example Cu2+, Ni2+, Zn2+, Cd2+ or Co2+.

Abstract: This invention concerns compounds with the formula: in which: R1=OH or NH2; OR2, OR3, OR4 and OR5 are alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate groups; and if R5=H if R2=R3=R4, then R2, R3 and R4?H; if R2=H, then R3?H and R4?H; if R3=H, then R2?H and R4?H; if R4=H, then R2?H and R3?H; if R5?H if R2=H, then R3?H and R4?H; if R3=H, then R2?H and R4?H; if R4=H, then R2?H and R3?H, their use as antibiotic agents and the process for synthesising them.

Abstract: The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a molecule, coming in the form of a zwitterion at physiological pH, with the general formula: where X?N or P; and Y?O or S.

Abstract: The invention relates to the use of compounds as new chiral selectors for separating the optical or enantiomeric isomers of a compound, wherein the chiral selector comprises at least one compound of formula (I): and at least one metal ion, for example Cu2+, Ni2+, Zn2+, Cd2+ or Co2+.

Abstract: The invention relates to a pharmaceutical composition containing as an active ingredient at least one compound selected from the compounds of the formula (II), in which the S atom is bonded to the nucleoside carbon at T or to the nucleoside carbon at 3?, and from the compounds of the following formula (III): formulae in which B is a nucleotide natural or modified base, x is 0, 1 or 2, and R1 and R represent a carbonated group or a molecular hydrocarbon remnant that can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si, X where X is halogen. The invention also relates to pharmaceutically acceptable carrier.

Abstract: Process for preparing a compound of the formula (I) R1-S(O)x—S(O)yR2 in which R1 represents a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen; R2, independently of R1, represents a carbon-containing group or a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen, and x and y are selected from 0 and 1 in such a way that the sum of x and y is not more than 1, characterized in that a compound of formula (II) R1-S(O)x—R3-Si(R4)(R5)(R6) in which R3 represents a hydrocarbon chain of two carbon atoms, which is optionally unsaturated and/or substituted, and R4, R5 and R6, which are identical or different, each represent, independently of one another, a

Abstract: The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.

Abstract: The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.

Abstract: The invention concerns a method for analyzing biological targets of DNA or RNA type, which comprises the following steps: a) contacting the targets to be analyzed (ICAM-20) with oligonucleotide probes (ISIS) labeled with a cofactor A of an enzyme E; b) adding, to the reaction medium, enzyme E corresponding to cofactor A and a substrate S of enzyme E, substrate S being converted by enzyme E into a compound C; c) measuring a signal representative of the activity of enzyme E on substrate S, for example the fluorescence intensity (I) of substrate S; and d) comparing this signal with the signal obtained when the oligonucleotide probes labeled with cofactor A (ISIS) are contacted with enzyme E and substrate S, under the same conditions, but in the absence of the targets, the difference between the two signals indicating the presence of complementary targets (ICAM-20) of the oligonucleotide probes.

Abstract: The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a molecule, coming in the form of a zwitterion at physiological pH, with the formula: where X?N or P; Y?O or S; R1 to R7 represent: —, H, or carbon chains, substituted or not, which may contain heteroatoms; except for betaine.

Abstract: This invention relates to an analytical support containing a plurality of oligonucleotides fixed on this support, where each of the nucleotides is marked by a fluorescent compound that presents a variation of fluorescence on the hybridization of each marked oligonucleotide with at complementary oligonucleotide. This support makes it possible to carry out an analysis of biological targets by measuring the variation of fluorescence in order to determine the hybridization of the targets with the oligonucleotides of the support.

Abstract: The invention concerns a method for analyzing biological targets of DNA or RNA type, which comprises the following steps: a) contacting the targets to be analyzed (ICAM-20) with oligonucleotide probes (ISIS) labeled with a cofactor A of an enzyme E; b) adding, to the reaction medium, enzyme E corresponding to cofactor A and a substrate S of enzyme E, substrate S being converted by enzyme E into a compound C; c) measuring a signal representative of the activity of enzyme E on substrate S, for example the fluorescence intensity (I) of substrate S; and d) comparing this signal with the signal obtained when the oligonucleotide probes labeled with cofactor A (ISIS) are contacted with enzyme E and substrate S, under the same conditions, but in the absence of the targets, the difference between the two signals indicating the presence of complementary targets (ICAM-20) of the oligonucleotide probes.

Abstract: This invention relates to an analytical support comprising a plurality of oligonucleotides fixed on this support, characterized in that each of said oligonucleotides is marked by a fluorescent compound that presents a variation of fluorescence on the hybridization of each marked oligonucleotide with a complementary oligonucleotide.